Joseph M Obeid1, Nolan A Wages2, Yinin Hu1, Donna H Deacon1, Craig L Slingluff3. 1. Department of Surgery, University of Virginia, Charlottesville, VA, USA. 2. Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA. 3. Department of Surgery, University of Virginia, Charlottesville, VA, USA. cls8h@virginia.edu.
Abstract
INTRODUCTION: Infiltration of non-small-cell lung cancer (NSCLC) by CD8+ T lymphocytes predicts improved patient survival; however, heterogeneity of intratumoral localization complicates this assessment. Strategies for tumor sampling may not accurately represent the whole tumor. We hypothesized that sampling strategies may alter the identification of tumors with high CD8 density and affect the prognostic significance. PATIENTS AND METHODS: Twenty-three primary NSCLC tumors were immunohistochemically stained for CD8 and were assessed using automated software with eight different sampling strategies or the whole tumor. Results of all sampling strategies were compared to the whole tumor counts (paired t tests, Pearson's r). Associations between CD8 densities and overall survival were assessed (log-rank test). RESULTS: Counts from all eight sampling strategies significantly correlated with whole tumor counts (p ≤ 0.001). However, the magnitude of CD8+ cell counts and categorization into high vs low infiltrate groups were affected by the sampling strategy. The most concordant values were derived from random sampling of 20 % of the tumor, a simulated core biopsy, or from sampling the tumor center. TIL infiltration was associated with survival when sampling the center (p = 0.038), but not the invasive margin (p > 0.2) or other strategies. CONCLUSION: Different tumor sampling strategies may yield discordant TIL density results and different stratification for risk assessment. Small biopsies may be particularly unrepresentative. Random sampling of larger tumor areas is recommended. Enumerating CD8+ T cells in the tumor center may have prognostic value.
INTRODUCTION: Infiltration of non-small-cell lung cancer (NSCLC) by CD8+ T lymphocytes predicts improved patient survival; however, heterogeneity of intratumoral localization complicates this assessment. Strategies for tumor sampling may not accurately represent the whole tumor. We hypothesized that sampling strategies may alter the identification of tumors with high CD8 density and affect the prognostic significance. PATIENTS AND METHODS: Twenty-three primary NSCLC tumors were immunohistochemically stained for CD8 and were assessed using automated software with eight different sampling strategies or the whole tumor. Results of all sampling strategies were compared to the whole tumor counts (paired t tests, Pearson's r). Associations between CD8 densities and overall survival were assessed (log-rank test). RESULTS: Counts from all eight sampling strategies significantly correlated with whole tumor counts (p ≤ 0.001). However, the magnitude of CD8+ cell counts and categorization into high vs low infiltrate groups were affected by the sampling strategy. The most concordant values were derived from random sampling of 20 % of the tumor, a simulated core biopsy, or from sampling the tumor center. TIL infiltration was associated with survival when sampling the center (p = 0.038), but not the invasive margin (p > 0.2) or other strategies. CONCLUSION: Different tumor sampling strategies may yield discordant TIL density results and different stratification for risk assessment. Small biopsies may be particularly unrepresentative. Random sampling of larger tumor areas is recommended. Enumerating CD8+ T cells in the tumor center may have prognostic value.
Authors: R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi Journal: Ann Oncol Date: 2014-09-11 Impact factor: 32.976
Authors: Annamaria Cadioli; Giulio Rossi; Matteo Costantini; Alberto Cavazza; Mario Migaldi; Thomas V Colby Journal: Am J Surg Pathol Date: 2014-04 Impact factor: 6.394
Authors: T Donnem; T K Kilvaer; S Andersen; E Richardsen; E E Paulsen; S M Hald; S Al-Saad; O T Brustugun; A Helland; M Lund-Iversen; S Solberg; B H Gronberg; S G F Wahl; L Helgeland; O Fløtten; M Pohl; K Al-Shibli; T M Sandanger; F Pezzella; L T Busund; R M Bremnes Journal: Ann Oncol Date: 2015-11-16 Impact factor: 32.976
Authors: Kurt A Schalper; Jason Brown; Daniel Carvajal-Hausdorf; Joseph McLaughlin; Vamsidhar Velcheti; Konstantinos N Syrigos; Roy S Herbst; David L Rimm Journal: J Natl Cancer Inst Date: 2015-02-03 Impact factor: 11.816
Authors: Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Sita S Withers; Daniel York; Jin W Choi; Kevin D Woolard; Renee Laufer-Amorim; Ellen E Sparger; Jenna H Burton; Stephen J McSorley; Arta M Monjazeb; William J Murphy; Robert J Canter; Robert B Rebhun Journal: Vet Comp Oncol Date: 2019-04-08 Impact factor: 2.613
Authors: Sonja Althammer; Tze Heng Tan; Andreas Spitzmüller; Lorenz Rognoni; Tobias Wiestler; Thomas Herz; Moritz Widmaier; Marlon C Rebelatto; Helene Kaplon; Diane Damotte; Marco Alifano; Scott A Hammond; Marie-Caroline Dieu-Nosjean; Koustubh Ranade; Guenter Schmidt; Brandon W Higgs; Keith E Steele Journal: J Immunother Cancer Date: 2019-05-06 Impact factor: 13.751